NorthStar Secures FDA Acceptance of Drug Master File for No-Carrier-Added Actinium-225

BELOIT, Wis.--(BUSINESS WIRE)--NorthStar Medical Radioisotopes, LLC (NorthStar), a leading radiopharmaceutical company, today announced that it received notice of the U.S. Food & Drug Administration's (FDA) acceptance of its Type II Drug Master File (DMF) submission for the company's no-carrier-added (n.c.a) Actinium-225 (Ac-225). This critical regulatory milestone formally establishes NorthStar's n.c.a. Ac-225 for use in development of radiopharmaceutical medicines and allows pharmaceutica.